» Articles » PMID: 39492838

Single-cell Transcriptomics Reveals IRF7 Regulation of the Tumor Microenvironment in Isocitrate Dehydrogenase Wild-type Glioma

Overview
Journal MedComm (2020)
Specialty Health Services
Date 2024 Nov 4
PMID 39492838
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in isocitrate dehydrogenase (IDH) are important markers of glioma prognosis. However, few studies have examined the gene expression regulatory network (GRN) in IDH-mutant and wild-type gliomas. In this study, single-cell RNA sequencing and spatial transcriptome sequencing were used to analyze the GRN of cell subsets in patients with IDH-mutant and wild-type gliomas. Through gene transcriptional regulation analysis, we identified the M4 module, whose transcription factor activity is highly expressed in IDH wild-type gliomas compared to IDH-mutants. Enrichment analysis revealed that these genes were predominantly expressed in microglia and macrophages, with significant enrichment in interferon-related signaling pathways. Interferon regulatory factor 7 (IRF7), a transcription factor within this pathway, showed the highest percentage of enrichment and was primarily localized in the core region of wild-type IDH tumors. A machine-learning prognostic model identified novel subgroups within the wild-type IDH population. Additionally, IRF7 was shown to promote the proliferation and migration of T98G and U251 cells in vitro, and its knockdown affected glioma cell proliferation in vivo. This study systematically established the regulatory mechanism of IDH transcriptional activity in gliomas at the single-cell level and drew a corresponding cell map. The study presents a transcriptional regulatory activity map for IDH wild-type gliomas, involving single-cell RNA sequencing and spatial transcriptomics to identify gene regulatory networks, machine learning models for IDH subtyping, and experimental validation, highlighting the role of IRF7 in glioma progression.

Citing Articles

Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics.

Chen S, Fei Y, Cai X, Wang C, Tong S, Zhang Z Front Endocrinol (Lausanne). 2025; 15():1528248.

PMID: 39850483 PMC: 11754047. DOI: 10.3389/fendo.2024.1528248.

References
1.
Rock R, Gekker G, Hu S, Sheng W, Cheeran M, Lokensgard J . Role of microglia in central nervous system infections. Clin Microbiol Rev. 2004; 17(4):942-64, table of contents. PMC: 523558. DOI: 10.1128/CMR.17.4.942-964.2004. View

2.
Tang F, Wang Y, Zeng Y, Xiao A, Tong A, Xu J . Tumor-associated macrophage-related strategies for glioma immunotherapy. NPJ Precis Oncol. 2023; 7(1):78. PMC: 10439959. DOI: 10.1038/s41698-023-00431-7. View

3.
He Y, Jiang Z, Chen C, Wang X . Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018; 37(1):327. PMC: 6310928. DOI: 10.1186/s13046-018-1002-1. View

4.
Wang L, Babikir H, Muller S, Yagnik G, Shamardani K, Catalan F . The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. Cancer Discov. 2019; 9(12):1708-1719. PMC: 7161589. DOI: 10.1158/2159-8290.CD-19-0329. View

5.
Yang Q, Li X, Chen H, Cao Y, Xiao Q, He Y . IRF7 regulates the development of granulocytic myeloid-derived suppressor cells through S100A9 transrepression in cancer. Oncogene. 2017; 36(21):2969-2980. DOI: 10.1038/onc.2016.448. View